- Home
- OGI vs EDIT Comparison
OGI vs EDIT Comparison
Compare OGI & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OGI
- EDIT
- Stock Information
- Founded
- OGI 2013
- EDIT 2013
- Country
- OGI Canada
- EDIT United States
- Employees
- OGI N/A
- EDIT N/A
- Industry
- OGI Biotechnology: Pharmaceutical Preparations
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OGI Health Care
- EDIT Health Care
- Exchange
- OGI Nasdaq
- EDIT Nasdaq
- Market Cap
- OGI 155.2M
- EDIT 156.5M
- IPO Year
- OGI N/A
- EDIT 2016
- Fundamental
- Price
- OGI $1.29
- EDIT $2.25
- Analyst Decision
- OGI
- EDIT Buy
- Analyst Count
- OGI 0
- EDIT 13
- Target Price
- OGI N/A
- EDIT $6.73
- AVG Volume (30 Days)
- OGI 528.0K
- EDIT 2.4M
- Earning Date
- OGI 08-12-2025
- EDIT 08-06-2025
- Dividend Yield
- OGI N/A
- EDIT N/A
- EPS Growth
- OGI N/A
- EDIT N/A
- EPS
- OGI 0.10
- EDIT N/A
- Revenue
- OGI $135,031,829.00
- EDIT $35,837,000.00
- Revenue This Year
- OGI $50.30
- EDIT N/A
- Revenue Next Year
- OGI $16.01
- EDIT N/A
- P/E Ratio
- OGI $12.75
- EDIT N/A
- Revenue Growth
- OGI 20.49
- EDIT N/A
- 52 Week Low
- OGI $0.85
- EDIT $0.91
- 52 Week High
- OGI $2.08
- EDIT $6.05
- Technical
- Relative Strength Index (RSI)
- OGI 45.78
- EDIT 63.76
- Support Level
- OGI $1.30
- EDIT $2.05
- Resistance Level
- OGI $1.51
- EDIT $2.55
- Average True Range (ATR)
- OGI 0.05
- EDIT 0.23
- MACD
- OGI -0.02
- EDIT 0.03
- Stochastic Oscillator
- OGI 4.44
- EDIT 66.29
About OGI Organigram Holdings Inc.
Organigram Global Inc is a licensed cultivator of cannabis and manufacturer of cannabis-derived goods in Canada. It is is focused on producing high-quality cannabis for adult recreational consumers. It has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Trailblazer, BOXHOT and DEBUNK. Organigram operates facilities in Moncton, New Brunswick and Lac-Superieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.